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Abstract The reported incidental prostate cancer prevalence
rates at radical cystoprostatectomy cover a range from 4 to
60 %. We investigated the influence of the histopathological
work-up on prostate cancer prevalence rates. We identified
114 patients who had undergone cystoprostatectomy for blad-
der cancer between 2000 and 2012. Complete histopatholog-
ical assessment was defined as follows: (i) complete embed-
ding of the prostate gland, (ii) sectioning of 15 or more
prostate sections, and (iii) processing as whole mount slides.
Prostate cancer prevalence rates derived from complete and
incomplete histopathological assessments were compared.
The overall prostate cancer prevalence rate was 59.6 %. A
mean of 14.4 macroscopic tissue sections (thickness 3–5 mm)
were sectioned. Sectioning ≥15 sections resulted in a prostate
cancer detection rate of 75 %, compared to 42.6 % when
sectioning <15 sections (p<0.001). Complete embedding
yielded a prostate cancer detection rate of 72.3 and of
23.1 % for partly embedded prostates (p<0.0001). Prostate
cancer was detected in 68.8 % of the whole mounted samples
and in 38.2 % of the samples sectioned as standard slides
(p<0.01); according to the criteria described by Epstein and
Ohori, 44.1 % of the detected prostate cancers were clinically
significant. The quality of the histopathological work-up sig-
nificantly influences prostate cancer detection rates and might
at least partially explain the highly variable reported incidental
prostate cancer prevalence rates at cystoprostatectomy (CP).
The high proportion of significant prostate cancer found in our
series calls for a careful surgical approach to the prostate
during CP.
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Introduction
With a proportion of 24.4 % of male malignancies, pros-
tate cancer represents the most common solid neoplasm
among men [28]. Bladder cancer makes up 6.3 % of all
cancers among men in Europe and ranks as the 4th most
common cancer for men, with approximately 95,000 new-
ly diagnosed cases each year [13, 28]. The prevalence of
both prostate and bladder cancers increases in the aging
population. As radical cystoprostatectomy (CP) is per-
formed mostly in elderly patients, the coincidental detec-
tion of both tumors is not uncommon. Highly variable
prevalence rates of incidental prostate cancer at radical CP
have been reported, ranging from 4 [30] to 60 % [29].
Importantly, the histopathological work-up of the prostate,
more specifically, the macroscopic section thickness [3,
11] and the embedding technique [3, 14], is known to
influence prostate cancer detection rates. Here, we
assessed the prevalence rate of incidental prostate cancer
in CP specimens in a highly industrialized town area and
compared our findings to the reported rates worldwide.
Furthermore, we analyzed the histopathological character-
istics, their potential clinical relevance, and the influence
of the histopathological technique on the detection of
incidental prostate cancer.
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Materials and methods
This retrospective study was approved by the local ethics
committee (EKBB). One hundred thirty-nine patients having
undergone radical CP for bladder cancer (n=133) and other
indications between 2000 and 2012 were identified by
searches in the archives of the Departments of Urology and
Pathology at University Hospital Basel and by searches in the
accounting systems. Twenty-five of these patients did not
qualify for the analysis because either prostate cancer had
been diagnosed prior to surgery or they had been treated for
other reasons (n=6) than bladder cancer like low-capacity
bladder or contracted, nonfunctional bladder after radiation
therapy. Finally, 114 men who had undergone radical CP for
bladder cancer were included in the analysis. The medical
reports were reviewed for individual patient characteristics.
The histopathology reports were screened for the TNM clas-
sification of bladder and prostate cancers and for tumor his-
tology, including Gleason score, surgical margins, maximal
tumor diameter, complete or partial sampling, and number of
macroscopic sections. All histological samples were reviewed
according to the current classifications (i.e., TNM 2009,
WHO 2004, ISUP 2005).
To determine the maximal tumor diameter, the edges of
each tumor were outlined and the resulting distances were
measured in millimeters; if a tumor was present in consecutive
sections, the greatest measurement in all three dimensions
(length, width, or depth) was considered the maximum diam-
eter. In patients with complete transurethral resection of blad-
der (TUR-B) tumors and no evidence of tumors in the bladder
at cystectomy, the final histology at TUR-B before the
cystectomy was noted. Radical CP samples were processed
in accordance with the descriptions in the guidelines of the
Swiss Society of Pathology [12]. For histopathological grad-
ing, the 2004 WHO classification was used.
For macroscopic tissue sectioning, a mean of 14.4 (median
15, range 2–37) sections with a thickness between 3 and 5mm
were used. Of the total 114 processed samples, 26 (23.1 %)
had been partially and 83 (76.1 %) had been completely
embedded. For five samples, no information on the complete-
ness of the embedding was available. Eighty (70.2 %) samples
were prepared as whole mount sections, and 34 (29.8 %)
samples were processed as standard specimen slides.
We applied the following most commonly used criteria for
nonsignificant prostate cancer [22]: (i) Gleason score ≤6 with-
out Gleason pattern 4 or 5, (ii) organ-confined disease, and
(iii) tumor volume <0.5 cm3.
To determine the maximal tumor diameter, the edges of
each tumor were outlined and the resulting distances were
measured in millimeters; if a tumor was present in consecutive
sections, the greatest measurement in all three dimensions
(length, width, or depth) was considered the maximum diam-
eter. Pathological reports did not encompass tumor volume
but did indicate tumor diameter. Based on the mathematical
formula of spherical volume (4/3 πr3), we calculated the
diameter for a tumor with a volume of 0.5 cm3 and concluded
that a tumor with a diameter larger than 1 cm would therefore
be defined as significant.
All statistical inference testing and data visualization were
performed using R 3.0.1. [24]. For continuous data, Wilcoxon
rank sum tests were used, and for categorical data, Fisher’s
exact tests or Pearson’s chi-squared tests were applied as
indicated. The clinical follow-up information regarding PSA
course, survival, progression, or recurrence was incomplete,
and the data quality did not allow for further statistical anal-
ysis. P values lower than 0.05 were considered statistically
significant.
Results
Detailed characteristics for all 114 bladder cancer patients are
given in Table 1. Most of the detected bladder cancers were
diagnosed as urothelial carcinomas (n=108; 94.7 %), while
the remaining diagnoses were small cell carcinoma,
sarcomatoid carcinoma, squamous cell carcinoma, mixed car-
cinoma, and urothelial dysplasia.
Incidental prostate cancer was identified in 68 (59.6 %) of
the 114 CP specimens. The patient characteristics for the
patients with incidental prostate cancer are given in Table 2.
All prostate cancers were histologically classified as adeno-
carcinomas. In three patients, high-grade prostatic
intraepithelial neoplasia (PIN) was diagnosed. Median age
of patients with prostate cancer was comparable to that of
the whole investigated population, and no significant differ-
ence in age between patients with (69.4 years) and without
(69.7 years) prostate cancer was observed. Four (5.9 %) had a
Gleason score of 4. The majority of patients (n=45) exhibited
a Gleason score of 5–6 (66.2 %), and 19 patients (27.9 %) had
Gleason scores ≥7. Sixty-one (89.7 %) of the 68 tumors
displayed organ-confined growth, while extra-capsular exten-
sions were observed in 7 (10.3 %). Of note, none of the 67
prostate cancer patients for whom the lymph node status had
been determined demonstrated lymph node metastases. The
mean number of resected lymph nodes was 15.5 (median
13.5; range 2–37). Overall, 62 (91.2 %) of the specimens
showed tumor-free surgical margins (R0), and 6 (8.8 %)
displayed positive margins (R1). Positive margins were iden-
tified dorsally (n=1), laterally (n=1), in the apex (n=2), and
the basis (n=2).
PSA had been tested prior to surgery for 32 patients and
upon follow-up for 20 patients. The mean PSA prior to sur-
gery was 2.78 ng/ml (median 1.55 ng/ml, range 0.03–
12 ng/ml). The mean preoperative PSA value of the groups
with prostate cancer (3.3 ng/ml) and without detected prostate
cancer (1.1 ng/ml) was significantly different (Fig. 1, p<0.05,
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Wilcoxon rank sum test). In the low PSA group (PSA
<4 ng/ml), prostate cancer was detected in 20 (70.4 %) of
the 27 patients; 7 (41.2 %) cases were significant. Prostate
cancer was detected in all five patients with a PSA >5 ng/ml.
The comparison of the PSA values prior to surgery (n=31)
correlated positively with the tumor diameter (p=0.0071,
Spearman rho=0.58, R2=0.33). After surgery, the PSA
dropped to a mean of 0.034 ng/ml (median <0.03, range
<0.03–0.09). Additionally, 30 (44.1 %) of the 68 detected
prostate cancers fulfilled the criteria for a significant carcino-
ma. Eighteen tumors had a Gleason pattern of 4 or higher, 23
featured a diameter greater than 10 mm, 7 were not organ
confined, and 13 met several of the criteria for clinical signif-
icance (Table 3). The mean preoperative PSA in the subgroup
of insignificant prostate cancer (1.4 ng/ml) was significantly
lower than the mean PSA in the subgroup of significant
prostate cancer (5.4 ng/ml, p=<0.01) (Fig. 1).
In the group with incidental prostate cancer, a mean of 16.4
(median 17, range 5–34) tissue sections were sectioned. Fewer
than 15 sections were used for 54 (47.4 %) of the prostates,
and 15 or more sections were used for 60 (52.6 %) prostates.
Table 2 Descriptive
characteristics of inci-
dentally detected pros-
tate cancer
Number of patients 68 %
Histology
Adeno-ca 68 100
T stadium
T2 2 2.9
T2a 34 50
T2b 4 5.9
T2c 21 30.9
T2 total 61 89.7
T3 1 1.5
T3a 6 8.8
T3 total 7 10.3
pN stage
N0 67 98.5
N1 0 0
Nx 1 1.5
Resected LN (n=
36)
Mean 15.5
Median 13.5
Range 2–37
Distant metastases
M1 0 0
M0 57 83.8
Unknown 11 16.2
Gleason score
Median 6
2+2 4 5.9
2+3 6 8.8
3+2 5 7.4
3+3 34 50
3+4 10 14.7
7 1 1.5
3+5 1 1.5
4+3 5 7.4
4+5 1 1.5
5+3 1 1.5
Tumor diameter
(mm)
n=68
Mean 9.6
Median 8
Range 1–44
Tumor volume
(cm3)
n=68
Mean 0.268
Range 0.0005–
44.6
Table 1 Descriptive
characteristics of bladder
cancer detected in
cystoprostatectomy
specimens
Number of patients 114
age (years)
median 69.7
range 44–88
T stage n %
Ta 1 0.9
cis 7 6.1
T1 13 11.4
T2 40 35.1
T3 2 1.8
T3a 18 15.8
T3b 15 13.2
T3 total 35 30.7
T4 total 18 15.8
Concomitant Cis 20 17.5
Grade
G2 18 16.8
G3 96 84.2
pN stage
N0 83 72.8
N1 18 15.8
N2 12 10.5
Nx 1 0.9
Distant metastases
M0 100 87.7
M1 1 0.9
Not reported 13 11.4
Resection margin
R0 101 88.6
R1 13 11.4
Histology
Urothelial carcinoma 108 94.7
Others 6 5.3
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This resulted in the detection of 23 (42.6 %) and 45 (75 %)
incidental prostate cancers (p<0.001; Fisher’s exact test),
respectively, as presented in Fig. 2. Eighty-three (76.1 %) of
the total 114 prostates were embedded completely, and 26
(23.9 %) were embedded partially. For five prostates, the
embedding technique was not reported. Prostate cancer was
detected in 60 (72.3 %) of the 83 completely embedded
samples and in 6 (23.1 %) of the 26 partially embedded
samples (p<0.0001; Fisher’s exact test; Fig. 2). Significant
prostate cancer was detected in 28 (33.7 %) of the 83
completely embedded samples and in 1 (3.8 %) of the 26
partially embedded samples (p<0.01; Fisher’s exact test).
We compared the rates of complete embedding with the
detection rate of prostate cancer in the periods between 2000
and 2006 and 2007 and 2012. The rates of completely embed-
ded samples in the two periods were 55.3 and 91.9 %, respec-
tively. The first period yielded an overall prostate cancer prev-
alence rate of 50 %, and the second period yielded 67.7 %.
Whole mount sections were used for 80 (70.2 %) samples,
and standard slides were used for 34 (29.8 %) samples. In 55
(68.8%) of the whole mount sections and in 13 (38.2%) of the
standard slides, prostate cancer could be detected (p<0.01;
Fisher’s exact test; Fig. 2).
Discussion
Here, we explored the prevalence of incidental prostate cancers
in CP specimens in a highly industrialized town area, where
most of the CP specimens are processed centrally at a single
pathology institute. Comparison of complete versus incomplete
specimen processing indicated prostate cancer prevalence rates
reaching up to 75 % for completely processed specimens.
Based on previous publications, including a total of 11,553
patients, the mean prevalence rates of prostate cancer at rad-
ical CP in Europe and globally were 25.2 and 26.5 %, respec-
tively (Table 4). Detection rates are influenced by technical
variables [3, 11], study populations [3], and geographic [23,
28] factors; e.g., studies from Asia generally reported lower
rates than those from the USA and Europe (Table 4). Com-
pared to these previously reported rates, the 59.6 % in our
study represent one of the highest published prevalence rates
of incidental prostate cancer in CP specimens (Table 4). Gen-
erating a best-case scenario and analyzing the subgroup of 53
patients with complete embedding, the use of 15 or more
sections and whole mount sections results in a prevalence rate
of 75.5 %. This extraordinary high proportion is unlikely to be
greatly biased by the retrospective nature of the study because
our study was based on a consecutive series of CP specimens.
Our high prevalence of incidental prostate cancer also clearly
exceeded the rates of most previous autopsy series [7]. Only
Sakr et al. discovered unexpected prostate cancer at a similarly
high rate of 55 and 64% of autopsied patients who had died in
their 6th and 7th decades, respectively, after a histological
examination of their whole prostates [25].
To the best of our knowledge, this is the first report on the
prevalence of incidental prostate cancer in CP specimens in
Switzerland. It could be speculated that the high prevalence in
an industrialized town area may be due to an increased expo-
sure to potential carcinogenic factors that drive prostate can-
cer. However, to date, there has been no published evidence
Fig. 1 Comparison of preoperative PSA values in the groups without,
with nonsignificant, and with significant prostate cancer
Table 3 Further criteria for the clinical relevance of prostate cancer (n =
patients with prostate cancer fulfilling the indicated criteria)
Number Percent
Gleason score including a pattern ≥4 18 26.5
pT stage ≥T3 7 10.3
Max tumor diameter >10 mm 23 33.8
More than one criterion for relevant cancer 13 19.1
<60 years 13 19.1
≥60 <75 years 35 51.5
≥75 years 20 29.4
Total clinical relevant tumors 30 44.1
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that a high prevalence of incidental prostate cancer could be
driven by exposure to carcinogens in the context of the sub-
stantial presence of chemical and pharmaceutical industries or
by other, as yet undefined, exposures in our region.
Instead, the extent of histological processing appears to be
the most influential factor to explain the high prostate cancer
prevalence (Fig. 2). Several published results have shown that
lower section thickness increases prostate cancer detection
rates [11, 30]. In our study, the prostates were processed into
3–5mm tissue slices and paraffin blocks, and sections from 15
or more tissue blocks significantly raised the prostate cancer
detection rates. Although the section number can depend on
the size of the prostate gland, our results suggest that prostate
cancer detection rates increased proportionally with the num-
ber of tissue blocks and sections. The same was true for
complete versus incomplete embedding of the prostate, which
is in line with other published series [3, 14]. Furthermore,
complete embedding significantly improved (p<0.01) the
detection of significant prostate cancer compared to partial
embedding in our series. The use of the whole mount tech-
nique [19] resulted in a significantly (p<0.01) higher prostate
cancer detection rate of 68.8%, compared to the use of regular
slides (38.2 %). As a caveat, 89.3 % of the prostates processed
as whole mount sections, but only 26.5 % of those processed
as regular slides were completely embedded. Finally, the
overall prostate cancer prevalence rate of 67.7 % between
2007 and 2012, when most of the samples were embedded
completely, indicates that a consequent use of complete em-
bedding, the use of whole mount sections, and/or a high
section number can significantly influence the prostate cancer
prevalence rates in CP series.
The clinical relevance of incidental prostate cancers detect-
ed at radical CP remains questionable. Two studies demon-
strated significantly worse survival after radical CP for pa-
tients with concurrent tumors [8, 27], while Pritchett found no
difference in the mortality rates [11]. In a recent series of 1476
patients, 22 % of the detected prostate cancers were classified
as significant. However, the most influential factor in this
series was not the presence of relevant prostate cancer but
prostatic infiltration of a urothelial carcinoma [6]. In our
series, almost half of the prostate cancers met criteria for
significant prostate cancer (Table 3) but none had detectable
lymph node metastases (Table 2). Our rate of clinically sig-
nificant prostate cancer is comparable to the other reported
rates (Table 4), even though the reported rates are diverse,
based on the different criteria being applied [22]. Elevated
Fig. 2 Detection rates of incidental prostate cancer, according to the pathological work-up. a <15 versus >15 prostate sections. bComplete versus partial
embedding. c Regular slides versus whole mount slides. The numbers in brackets indicate the percentage of specimens in each indicated group
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Table 4 Worldwide reported rates of incidental prostate cancer in cystoprostatectomy specimens
Author Region Year N Mean
age
Section
thickness
(mm)
Sampling PCa
total
PCa
%
Significant
PCa (%)
North America
Winfield [3] Iowa, USA 1987 80 63.7 Complete 22 27.5 11 (50 %)
Pritchett [11] South Carolina, USA 1988 165 65 Partial 45 27.3 8 (17.8 %)
Montie [11] Cleveland, USA 1989 84 62 4–5 Complete 39 46.4 6 (15 %)
Kabalin [3] Standford, USA 1989 66 64 3 Complete 25 37.9 3 (12 %)
Abbas [11] Miami, USA 1996 40 64.3 2–3 Partial 18 45
Ward [3] Rochester, USA 2004 129 69 30 23.3 18 (60 %)
Revelo [11] Nashville, USA 2004 121 67.4 5 Complete 50 41.3 24 (48 %)
Abdelhady [3] Ontario, Canada 2007 204 67 Complete 58 28.4 18 (31 %)
Weizer [3] Michigan, USA 2007 35 65 16 45.7 4 (25 %)
Bruins [6] Los Angeles, USA 2013 1476 69 3–5 559 37.9 123 (8.3 %)
Europe
Moutzouris [11] Athens, Greece 1999 59 66.5 5 Complete 16 27.1
Conrad [11] Hamburg, Germany 2001 133 60 3 Complete 58 43.6 11 (19 %)
Prange [3] Hamburg, Germany 2001 85 64 4 Complete 41 49.0 4 (10 %)
Cindolo [3] Naples, Italy 2001 165 69 3 Partial/complete 17 10.3
Kouriefs [3] Gillinghan, England 2005 128 23 18
Delongchamp [11] Paris, France 2005 141 62 4 Complete 20 14.2 14 (70 %)
Montironi [3] Ancona, Italy 2005 132 61 Complete 55 42 %
Ruffion [11] Lyon, France 2005 100 62 2.5 Complete 51 51 6 (12 %)
Rocco [11] Milano, Italy 2006 63 67 3 Complete 34 54 12 (35 %)
Winkler [29] London, England 2007 97 2 Partial 58 60 31 (53 %)
Barbisan [5] Marche, Italy 2008 248 68 3 123 49.6 23 (18.7 %)
Mazzuchelli [18] Ancona, Italy 2009 248 68 3 Complete 123 49.6 23 (18.7 %)
Gakis [15] Tübingen, Germany 2010 95 68 4–5 26 27.4 7 (27 %)
Buse [8] Germany 2012 1122 65.6 2–5 200 17.8
Fritsche [14] Regensburg, Germany 2012 295 68 4 Partial/complete 91 30.8 41 (45 %)
Alsinnawi [2] Dublin, Ireland 2012 108 64 4 Complete 35 32.4 10 (28.5 %)
Sruogis [27] Vilnius, Lithuania 2012 81 61.3 27 33.3 13 (48.1 %)
Pignot [21] France 2013 4251 70.2 905 21.7
Wetterauer Basel, Switzerland 2013 115 68.9 3–5 Partial/complete 68 59.6 40 (58.8 %)
Asia
Lee [30] Kweishan, Taiwan 2006 248 63 5 Complete 10 4
Yang [30] Thaijung, Taiwan 1999 49 67.8 3 Complete 16 32.6
Nakagawa [20] Tokyo, Japan 2009 349 65 5 91 26.1 68 (74.7 %)
Jin [16] Hangzhou, China 2008 264 70.9 5 Complete 37 14 12 (32.4 %)
Zhu [30] Shanghai, China 2009 92 67.1 5 Complete 3 3.3 1 (33.3 %)
Australia
Ahmadi [1] Sydney, Australia 2012 129 50 38.8 35 (70 %)
Middle east
Aydin [3] Turkey 1999 121 67.1 17 14
Hosseini [3] Theran, Iran 2007 50 62.5 Partial 7 14 4 (57 %)
Aytac [4] Bursa, Turkey 2011 300 62 3–5 Complete 60 20 40 (66.7 %)
North America 2400 862 35.9
Europe 7551 1903 25.2
Asia 1002 157 15.7
Australia 129 50 38.8
Middle East 471 84 17.8
Total 11,553 3056 26.5
634 Virchows Arch (2014) 465:629–636
PSA may be predictive of the presence of significant cancer
and a large tumor diameter, as suggested by our comparison;
however, the patient numbers are low, and the clinical data are
insufficient for making final conclusions about these findings.
Srougi et al. proposed a cystectomy in combination with the
enucleation of adenomas [3], and TUR-P with preservation of
the capsule prior to cystectomy was reported as an option by
Colombo et al. [10]. These techniques might be applicable for
selected patients for whom the preservation of potency is
paramount, but in light of our findings, they may stand against
the principles of cancer surgery. If attempted though, it seems
reasonable to perform prostate biopsy before such surgery as
even low PSA values cannot exclude the presence of prostate
cancer (Fig. 1). Given the high risk of prostate cancer in
patients undergoing CP, special attention to the removal of
the prostate seems advisable. Once the presence of prostate
cancer has been confirmed after CP, specific oncologic follow-
up may be indicated. At least in high-risk prostate cancer, the
oncologic follow-up might include regular PSA monitoring in
order to detect residual, recurrent, or metastatic disease.
It has been suggested that bladder cancer patients have an
increased risk of being diagnosed with prostate cancer [17,
26]. In fact, a higher coincidence rate of bladder and prostate
tumors compared to their presence in the general population
has been reported [9]. Such a correlation may be explained
partly by the relatively high age of patients and the fact that
exposure of patients with either tumor type to urologists
favors the detection of other urogenital cancers, if present.
Finally, there is currently no compelling evidence for a com-
mon link between prostate and bladder cancers.
Several studies have reported the influence of specific
pathologic sampling techniques on prostate cancer detection
rates in CP specimen. To the best of our knowledge, we are the
first to assess the influence of specific aspects of pathologic
sampling within one series at a single Pathology Institute and
to report the incidental prevalence rate of PCa at CP in
Switzerland. Compared to the extremely variable reported
rates of incidentally discovered prostate cancers, our reported
rate of 59.6 % ranks among the highest published rates.
Subgroup analysis of samples with complete embedding, the
use of 15 or more sections, and whole mount sections resulted
in prevalence rates of more than 75 % in our series.
Conclusions
We report a high prevalence of incidental prostate cancer at
CP of 59.6 %. This is more than twice as high as the mean
reported European and worldwide prevalence of 26.5 %. We
demonstrate the paramount importance of a complete histo-
pathological work-up for estimating the true prevalence of
prostate cancer in a given population and for the detection of
significant prostate cancer. Our results call for a careful surgi-
cal approach to the prostate at radical cystoprostatectomy.
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